These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Warfarin: a quality assurance model for concurrent drug monitoring. Mattei TJ; Karnack CM; Rihn TL; Eder RA Hosp Pharm; 1985 Apr; 20(4):235-7, 240-1. PubMed ID: 10270729 [TBL] [Abstract][Full Text] [Related]
4. Financial impact of formulary revision of second-generation cephalosporins. Andrews JD; Hafting S Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499 [TBL] [Abstract][Full Text] [Related]
5. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions. Hayman JN; Sbravati EC Am J Hosp Pharm; 1985 Jun; 42(6):1343-7. PubMed ID: 4014250 [TBL] [Abstract][Full Text] [Related]
6. Preprinted order sheet to enhance antibiotic prescribing and surveillance. Kowalsky SF; Echols RM; Peck F Am J Hosp Pharm; 1982 Sep; 39(9):1528-9. PubMed ID: 7137193 [No Abstract] [Full Text] [Related]
7. Cost, motion, and time studies comparing a new cephalosporin admixture system. Turco SJ Hosp Pharm; 1982 Dec; 17(12):653-8. PubMed ID: 10257925 [No Abstract] [Full Text] [Related]
8. Monitoring antibiotic prescriptions can reduce use and cost of drugs. Douglas AS Mod Healthc; 1984 Oct; 14(13):106-7. PubMed ID: 10268397 [No Abstract] [Full Text] [Related]
9. Drug control program used to cut costs. Ollis LN; Britton HL Healthc Financ Manage; 1984 May; 38(5):98-100. PubMed ID: 10315555 [No Abstract] [Full Text] [Related]
10. Controlling moxalactam and cefotaxime use with a target drug program. Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791 [TBL] [Abstract][Full Text] [Related]
12. Methods of controlling cephalosporin use in Canadian hospitals. Godin JP; Sketris IS; Merrett RA; Marrie TJ Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052 [TBL] [Abstract][Full Text] [Related]
13. Case studies of pharmacy involvement in hospital-based home health care. Hamot Medical Center. Meyer JD; Brundige ML; Kelly WN Am J Hosp Pharm; 1986 Feb; 43(2):406-9. PubMed ID: 3953605 [No Abstract] [Full Text] [Related]
14. Cost-effective management of DUE (drug utilization evaluation) policy through a pharmacy clerkship. Julius HC Hosp Formul; 1993 Sep; 28(9):789-91. PubMed ID: 10128394 [TBL] [Abstract][Full Text] [Related]
15. Impact of parenteral cephalosporin regulation on pharmacy costs. Ryan JL; Francese J Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198 [No Abstract] [Full Text] [Related]
16. Benefits of clinical pharmacy services in a community hospital. Williams LE Hosp Pharm; 1993 Aug; 28(8):759-63, 766-7. PubMed ID: 10127576 [TBL] [Abstract][Full Text] [Related]
17. Cephalosporin-use restrictions in teaching hospitals. McCloskey WW; Johnson PN; Jeffrey LP Am J Hosp Pharm; 1984 Nov; 41(11):2359-62. PubMed ID: 6507437 [TBL] [Abstract][Full Text] [Related]
18. How we developed a comprehensive data base for antibiotic use. Vandel K Pharm Times; 1987 Apr; 53(4):98-100. PubMed ID: 10281924 [No Abstract] [Full Text] [Related]
19. An approach to regulating cephalosporin use and costs. Ryan JL; Francese J Hosp Formul; 1980 Sep; 15(9):674-6. PubMed ID: 10248357 [No Abstract] [Full Text] [Related]